Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PPP5C | P53041 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380454 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1TDP1PDK1KMT2A | |
| SCHEMBL19519667 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1PDK1 | |
| SCHEMBL10142208 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1TDP1PDK1KMT2A | |
| SCHEMBL6933436 | 0.78 | MGAM (0.37) | MGAMCA1CA2GAASI | |
| SCHEMBL10142408 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1TDP1PDK1TSHR | |
| SCHEMBL19352626 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TDP1KMT2ACA1 | |
| SCHEMBL18313127 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TDP1KMT2ACA1 | |
| SCHEMBL10291150 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1TDP1PDK1TSHR | |
| SCHEMBL19519551 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1TDP1PDK1TSHR | |
| SCHEMBL13644905 | 0.75 | LMNA (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | SMN1; SMN2 71/4885ALDH1A1 4309/4885TDP1 46/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | SMN1; SMN2 1937/4885ALDH1A1 3407/4885TDP1 396/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | SMN1; SMN2 3956/4885ALDH1A1 3066/4885TDP1 1736/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | SMN1; SMN2 4743/4885ALDH1A1 4382/4885TDP1 4253/4885 |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | HSP90B1, HSP90AB2P, HSP90AB1 | SMN1; SMN2 3057/4885ALDH1A1 2718/4885TDP1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.